Phase 3 trial shows inebilizumab reduces flares in IgG4-related disease (10% vs 60% in placebo; HR 0.13, p<0.001) and

Social Author Image
https://pbs.twimg.com/profile_images/1770889097185316864/wAAgY2KJ_normal.jpg
Tweet Author
DrNatashaSalman
Social Author Name
Natasha Salman, DO
Tweet Content
Phase 3 trial shows inebilizumab reduces flares in IgG4-related disease (10% vs 60% in placebo; HR 0.13, p<0.001) and boosts remission rates without background immunosuppressants. CD19+ B-cell depletion shows promise as a new treatment. #Rheum @RheumNow https://t.co/7iSyPfnMV0 https://t.co/M51b0dipMs
Links
Inebilizumab for Treatment of IgG4-Related Disease | NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2409712
https://x.com/DrNatashaSalman/status/1911917391921221767/photo/1

✅ T2T in #Lupus 👀 ⬇️⬇️ 📥 LINK https://t.co/F8w8qRZdsS #NosVemosEnPANLAR2025 https://t.co/JNx1wdwMb4

Social Author Image
https://pbs.twimg.com/profile_images/1531656868095004674/j5bxAXbf_normal.jpg
Tweet Author
Lupusreference
Social Author Name
Laurent ARNAUD
Tweet Content
✅ T2T in #Lupus 👀 ⬇️⬇️ 📥 LINK https://t.co/F8w8qRZdsS #NosVemosEnPANLAR2025 https://t.co/JNx1wdwMb4
Links
Framework for implementing treat-to-target in systemic lupus erythematosus rout… https://authors.elsevier.com/a/1kdub5alwYF%7EsD
https://x.com/Lupusreference/status/1905138987330568416/photo/1

Our Chief Medical Editor Leonard H. Calabrese, DO, (@LCalabreseDO) shares his reflections on the book: Masterclass in Me

Social Author Image
https://pbs.twimg.com/profile_images/1593277269715320832/zvFkXl5a_normal.jpg
Tweet Author
HealioRheum
Social Author Name
Healio Rheumatology
Tweet Content
Our Chief Medical Editor Leonard H. Calabrese, DO, (@LCalabreseDO) shares his reflections on the book: Masterclass in Medicine: Lessons from the Experts @ClevelandClinic https://t.co/gZhbrBLcnR
Links
Book review: Masterclass in Medicine assembles all-star roster to guide physici… https://www.healio.com/news/rheumatology/20250415/book-review-masterclass-in-me…

Anti-muscarinic 3 Abs are assoc w/ severe GI Dz in systemic Sclerosis. 132 SSc pts (enrich for GI Sxs) - 39% had anti-M

Social Author Image
https://pbs.twimg.com/profile_images/1215290012490702848/mq73skc3_normal.jpg
Tweet Author
RheumNow
Social Author Name
Dr. John Cush
Tweet Content
Anti-muscarinic 3 Abs are assoc w/ severe GI Dz in systemic Sclerosis. 132 SSc pts (enrich for GI Sxs) - 39% had anti-M3R Abs; 25% high-titer M3R+. Hi titer M3R+ pts had more diffuse Dz (44% vs 23%), GI severity (91% vs 70%), RNPC3+ (18% vs 6%), U1RNP+(21 vs 2%) https://t.co/j8ZWFY4fgx
16 April 2025
Genetic Analysis of Asymptomatic Antinuclear Antibody Positive Patients

A large scale genomic population study found antinuclear antibodies (ANA) in up to 14% of the population; most with ANA are asymptomatic, and ANA production is not associated with significant genetic risk. 

Asymptomatic individuals who were either ANA positive or ANA negative from the All of Us Research Program genomics were studied. A cumulative genetic risk score for lupus was constructed using previously reported genome‐wide significant loci.

16 April 2025
Genomics and Future Drug Targets for Osteoarthritis

A Nature article details the results of an osteoarthritis, genome-wide association study meta-analyses across up to 489,975 cases and 1,472,094 controls, establishing 962 independent associations, 513 of which have not been previously reported. Results were published this week in the journal Nature.

Rheums! Have a rheumatology question or case for Dr. Cush? Record it here and we may feature it on an upcoming podcast.

Social Author Image
https://pbs.twimg.com/profile_images/1215290012490702848/mq73skc3_normal.jpg
Tweet Author
RheumNow
Social Author Name
Dr. John Cush
Tweet Content
Rheums! Have a rheumatology question or case for Dr. Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/uLoRmsAkiG https://t.co/ExthuSBSXs
Links
Submit Podcast Question or Comment | RheumNow https://buff.ly/VAUipdb

RheumNow Live 2025 is now available On Demand For the first time, https://t.co/4UQlqwujiR is offering exclusive access

Social Author Image
https://pbs.twimg.com/profile_images/1215290012490702848/mq73skc3_normal.jpg
Tweet Author
RheumNow
Social Author Name
Dr. John Cush
Tweet Content
RheumNow Live 2025 is now available On Demand For the first time, https://t.co/4UQlqwujiR is offering exclusive access to: ✅ 7 STEP Talks from top rheumatology experts ✅ 21 Powerful lectures and Q & A Panels answering real-world questions ✅ All speaker slides and handouts https://t.co/saW9WH4djO
Links
RheumNow http://RheumNow.Live

In a murine model of Kawasaki Dz vasculitis- depleting gut microbiota reduces KD like vasculitis. CV lesions were assoc

Social Author Image
https://pbs.twimg.com/profile_images/1215290012490702848/mq73skc3_normal.jpg
Tweet Author
RheumNow
Social Author Name
Dr. John Cush
Tweet Content
In a murine model of Kawasaki Dz vasculitis- depleting gut microbiota reduces KD like vasculitis. CV lesions were assoc w/ decrease in Akkermansia muciniphila and Faecalibacterium prausnitzii. Replacement attenuated these findings. https://t.co/Hnij8TWkYy https://t.co/wEuVcuAZ5j
Links
Intestinal Microbiota Contributes to the Development of Cardiovascular Inflamma… https://buff.ly/1yZ7J1T

Systematic review of >90 studies on Pregnancy and RA risk indicates that parity, gravidity, infertility, pregnancy lo

Social Author Image
https://pbs.twimg.com/profile_images/1215290012490702848/mq73skc3_normal.jpg
Tweet Author
RheumNow
Social Author Name
Dr. John Cush
Tweet Content
Systematic review of >90 studies on Pregnancy and RA risk indicates that parity, gravidity, infertility, pregnancy loss do not adversely affect RA development. But low birthweight was assoc w/ RA Dx/severity, and pre-eclampsia incr risk of subsequent RA Dx. https://t.co/jVa4tmSqvj
Subscribe to
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×